Several other research analysts have also recently issued reports on the company. Credit Suisse Group set a $88.00 price objective on China Biologic Products and gave the stock a hold rating in a research note on Friday, March 8th. ValuEngine upgraded China Biologic Products from a hold rating to a buy rating in a research note on Friday, March 1st. Finally, Jefferies Financial Group cut China Biologic Products from a hold rating to an underperform rating and reduced their price objective for the stock from $67.00 to $62.00 in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $78.00.
Shares of NASDAQ:CBPO remained flat at $$92.70 during trading on Thursday. The stock had a trading volume of 126,291 shares, compared to its average volume of 294,182. China Biologic Products has a 1 year low of $60.08 and a 1 year high of $107.44. The stock has a market capitalization of $3.65 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 4.91 and a beta of 1.28.
Several large investors have recently made changes to their positions in the company. Dalton Investments LLC raised its position in China Biologic Products by 51.1% in the first quarter. Dalton Investments LLC now owns 113,851 shares of the biopharmaceutical company’s stock valued at $10,389,000 after purchasing an additional 38,500 shares during the period. Alpine Global Management LLC purchased a new position in China Biologic Products in the first quarter valued at about $480,000. Laurion Capital Management LP purchased a new position in China Biologic Products in the first quarter valued at about $317,000. Parametrica Management Ltd purchased a new position in China Biologic Products in the first quarter valued at about $334,000. Finally, Nikko Asset Management Americas Inc. purchased a new position in China Biologic Products in the first quarter valued at about $4,966,000. Hedge funds and other institutional investors own 37.39% of the company’s stock.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
See Also: Are FAANG stocks a good investment?
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.